| 2025-08-06 | +56.9% | earnings | Seeking Alpha | Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth |
| 2025-08-06 | +56.9% | earnings | Seeking Alpha | Myriad Genetics, Inc. 2025 Q2 - Results - Earnings Call Presentation |
| 2025-08-06 | +56.9% | news | Seeking Alpha | Myriad Genetics outlines high single-digit to low double-digit growth target through cancer care continuum focus |
| 2025-08-06 | +56.9% | earnings | Seeking Alpha | Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript |
| 2025-08-06 | +56.9% | earnings | Seeking Alpha | Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth - Seeking Alpha |
| 2025-05-07 | -45.7% | earnings | Seeking Alpha | Myriad Genetics, Inc. 2025 Q1 - Results - Earnings Call Presentation |
| 2025-05-07 | -45.7% | earnings | Seeking Alpha | Myriad genetics lowers 2025 revenue guidance by $35M amid GeneSight challenges |
| 2025-05-07 | -45.7% | news | Yahoo Finance | Why Myriad Genetics (MYGN) Stock Is Down Today - Yahoo Finance |
| 2025-05-07 | -45.7% | earnings | Seeking Alpha | Myriad Genetics, Inc. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ:MYGN) 2025-05-07 - Seeking Alpha |
| 2025-05-06 | -44.1% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2025-08-05 | +42.2% | earnings | Seeking Alpha | Myriad Genetics Non-GAAP EPS of $0.05 beats by $0.06, revenue of $213.1M beats by $10.8M |
| 2025-08-05 | +42.2% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2024-05-07 | +19.8% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2024-11-01 | -19.0% | news | Seeking Alpha | Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage - Seeking Alpha |
| 2025-11-04 | -18.7% | expansion | Seeking Alpha | Myriad Genetics outlines expanded cancer care focus and launches new MyRisk panel to drive 2026 growth |
| 2025-11-04 | -18.7% | earnings | Seeking Alpha | Myriad Genetics, Inc. (MYGN) Q3 2025 Earnings Call Transcript |
| 2025-11-04 | -18.7% | earnings | Seeking Alpha | Myriad Genetics, Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2025-11-04 | -18.7% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2025-11-04 | -18.7% | news | StockStory | Why Myriad Genetics (MYGN) Stock Is Down Today - StockStory |
| 2025-11-04 | -18.7% | news | TradingView | Why Myriad Genetics (MYGN) Stock Is Down Today - TradingView |
| 2025-11-03 | -18.7% | earnings | Seeking Alpha | Myriad Genetics Non-GAAP EPS of $0.00 beats by $0.01, revenue of $205.7M beats by $0.56M |
| 2025-11-03 | -18.7% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2025-11-03 | -18.7% | news | Quiver Quantitative | Myriad Genetics Reports Third Quarter 2025 Financial Results, Announces Strategic Collaboration with SOPHiA GENETICS - Quiver Quantitative |
| 2025-11-03 | -18.7% | earnings | StockStory | Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock Drops - StockStory |
| 2025-11-03 | -18.7% | earnings | Yahoo Finance | Myriad Genetics (MYGN) Reports Break-Even Earnings for Q3 - Yahoo Finance |
| 2022-11-01 | -18.5% | legal | SEC EDGAR | MYGN 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-02-24 | -16.3% | legal | SEC EDGAR | MYGN 8-K: 2.02, 5.02, 7.01 (SEC Filing) |
| 2026-03-02 | +15.6% | news | Stock Titan | Myriad Genetics (MYGN) CPO has shares withheld to cover taxes - Stock Titan |
| 2026-03-02 | +15.6% | news | Stock Titan | New breast cancer test detects residual disease beyond standard scans - Stock Titan |
| 2023-02-28 | +15.4% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2021-08-03 | +12.5% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2024-10-09 | -11.6% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2026-04-14 | +11.1% | legal | MT Newswires | Myriad Genetics Secures Japanese Regulatory Approval For Prostate Cancer Diagnostic Test |
| 2026-04-14 | +11.1% | news | GlobeNewswire | Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan |
| 2026-04-14 | +11.1% | news | Stock Titan | Myriad Genetics (NASDAQ: MYGN) sets 2026 votes and outlines cancer-focused growth - Stock Titan |
| 2026-04-14 | +11.1% | news | Stock Titan | Japan clears Myriad test for prostate cancer patients using Lynparza - Stock Titan |
| 2026-04-13 | +10.7% | news | StockStory | 1 Cash-Burning Stock to Target This Week and 2 We Question |
| 2026-04-13 | +10.7% | news | MSN | Should You Hold Myriad Genetics Stock in Your Portfolio Right Now? - MSN |
| 2025-01-15 | -10.1% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2026-04-09 | -9.3% | news | GlobeNewswire | Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting |
| 2026-04-09 | -9.3% | news | Stock Titan | Myriad brings 4 SGO studies, including ovarian recurrence data - Stock Titan |
| 2025-09-10 | +9.1% | news | Seeking Alpha | Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript |
| 2023-11-09 | -8.8% | legal | SEC EDGAR | MYGN 8-K: 8.01 and (SEC Filing) |
| 2023-08-03 | -8.6% | legal | SEC EDGAR | MYGN 8-K: 2.02, 3.02, 8.01 (SEC Filing) |
| 2025-12-01 | -7.7% | news | StockStory | Why Myriad Genetics (MYGN) Stock Is Trading Lower Today - StockStory |
| 2026-02-24 | +7.6% | earnings | Seeking Alpha | Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth |
| 2026-02-24 | +7.6% | earnings | Seeking Alpha | Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y |
| 2026-02-24 | +7.6% | earnings | Seeking Alpha | Myriad Genetics outlines $860M–$880M revenue target for 2026 while advancing cancer care continuum strategy |
| 2026-02-24 | +7.6% | earnings | Seeking Alpha | Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript |
| 2026-02-24 | +7.6% | earnings | Seeking Alpha | Myriad Genetics, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2026-02-24 | +7.6% | news | Finviz | Why Myriad Genetics (MYGN) Stock Is Trading Up Today - Finviz |
| 2026-02-24 | +7.6% | earnings | Seeking Alpha | Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth - Seeking Alpha |
| 2026-02-24 | +7.6% | earnings | TradingView | MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down - TradingView |
| 2026-02-24 | +7.6% | earnings | Seeking Alpha | Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y (MYGN:NASDAQ) - Seeking Alpha |
| 2022-01-04 | -7.4% | legal | SEC EDGAR | MYGN 8-K: 5.02 (SEC Filing) |
| 2023-09-29 | -7.3% | news | GuruFocus | Is Myriad Genetics (MYGN) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap - GuruFocus |
| 2021-11-02 | -7.1% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2025-05-02 | +7.1% | news | StockStory | Myriad Genetics (MYGN) Research Report - StockStory |
| 2025-05-02 | +7.1% | earnings | Seeking Alpha | Myriad Genetics: Significantly Undervalued With Profitability In Sight - Seeking Alpha |
| 2023-10-31 | +7.0% | legal | SEC EDGAR | MYGN 8-K: 1.01 and (SEC Filing) |
| 2025-01-16 | -6.6% | news | Seeking Alpha | Myriad Genetics: Navigating Through A Setback (NASDAQ:MYGN) - Seeking Alpha |
| 2025-08-20 | +6.5% | news | Seeking Alpha | ANGLE plc partners with Myriad Genetics to advance cancer diagnostics |
| 2026-01-13 | -6.3% | earnings | Quiver Quantitative | MYRIAD GENETICS Q4 2025 Earnings Preview: Recent $MYGN Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative |
| 2021-09-24 | -6.3% | news | The Motley Fool | Myriad Genetics - MYGN - Stock Price & News - The Motley Fool |
| 2022-08-04 | +6.1% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2024-02-27 | -5.8% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2026-01-12 | -5.7% | earnings | Seeking Alpha | Myriad Genetics Q4 and 2025 revenue ranges include consensus |
| 2026-01-12 | -5.7% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2026-03-03 | +5.6% | news | Yahoo Finance | Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - Yahoo Finance |
| 2026-03-03 | +5.6% | news | Finviz | Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - Finviz |
| 2026-03-10 | +5.5% | news | StockStory | Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know - StockStory |
| 2026-03-10 | +5.5% | news | StockStory | 3 Reasons to Sell MYGN and 1 Stock to Buy Instead - StockStory |
| 2026-03-10 | +5.5% | news | TradingView | Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know - TradingView |
| 2025-10-03 | +5.3% | legal | SEC EDGAR | MYGN 8-K: 5.02 (SEC Filing) |
| 2023-07-06 | +5.3% | legal | SEC EDGAR | MYGN 8-K: 1.01, 2.03, 8.01 (SEC Filing) |
| 2021-05-03 | +5.0% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2021-12-14 | +4.9% | legal | SEC EDGAR | MYGN 8-K: 5.02 and (SEC Filing) |
| 2025-10-07 | -4.6% | legal | SEC EDGAR | MYGN 8-K: 5.02 and (SEC Filing) |
| 2025-03-12 | -4.6% | analyst | Schaeffer's Investment Research | Medical Equipment Stock Jumps on Upgrade - Schaeffer's Investment Research |
| 2025-06-05 | -4.3% | legal | SEC EDGAR | MYGN 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-12-08 | +4.1% | earnings | StockStory | Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q3 Earnings? - StockStory |
| 2023-06-02 | -4.0% | legal | SEC EDGAR | MYGN 8-K: 5.02, 5.03, 5.07 (SEC Filing) |
| 2025-10-17 | -3.8% | legal | Finviz | 2 Unpopular Stocks That Deserve a Second Chance and 1 That Underwhelm - Finviz |
| 2023-11-06 | +3.8% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2023-10-05 | -3.8% | legal | SEC EDGAR | MYGN 8-K: 5.02, 7.01 (SEC Filing) |
| 2022-07-27 | +3.6% | legal | SEC EDGAR | MYGN 8-K: 1.01, 2.03 (SEC Filing) |
| 2026-03-11 | -3.6% | news | The Globe and Mail | Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc - The Globe and Mail |
| 2024-09-12 | +3.6% | executive | Yahoo Finance | Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN) - Yahoo Finance |
| 2026-03-27 | -3.6% | news | Stock Titan | Vanguard (MYGN) amendment shows 0 shares; subsidiaries disaggregate holdings - Stock Titan |
| 2026-04-16 | -3.6% | expansion | Zacks | Tempus AI Expands Strategic Partnership Amid Oncology Boom |
| 2026-04-16 | -3.6% | news | GlobeNewswire | Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 |
| 2026-04-16 | -3.6% | news | Stock Titan | Breast cancer treatment data lead Myriad's 2 AACR podium talks - Stock Titan |
| 2026-04-16 | -3.6% | expansion | TradingView | Tempus AI Expands Strategic Partnership Amid Oncology Boom - TradingView |
| 2026-04-16 | -3.6% | news | Meyka | MYGN Insider Selling: Two Officers Dispose Shares April 16, 2026 - Meyka |
| 2026-02-23 | +3.6% | earnings | Seeking Alpha | Myriad Genetics Non-GAAP EPS of $0.04 beats by $0.06, revenue of $209.8M beats by $2.24M |
| 2026-02-23 | +3.6% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2026-02-23 | +3.6% | earnings | Quiver Quantitative | Myriad Genetics (MYGN) Stock Falls on Q4 2025 Earnings - Quiver Quantitative |
| 2026-02-23 | +3.6% | news | Stock Titan | New cancer and prenatal tests aimed to drive growth at Myriad Genetics - Stock Titan |
| 2026-02-23 | +3.6% | earnings | StockStory | Myriad Genetics’s (NASDAQ:MYGN) Q4 CY2025 Sales Top Estimates, Stock Jumps 22% - StockStory |
| 2026-02-23 | +3.6% | news | TradingView | iRhythm, agilon health, GoodRx, Fortrea, and Myriad Genetics Stocks Trade Down, What You Need To Know - TradingView |
| 2026-02-27 | +3.5% | news | TradingView | PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know - TradingView |
| 2025-11-25 | -3.3% | news | Seeking Alpha | Myriad Genetics partners to use AI to measure breast cancer risk |
| 2025-11-25 | -3.3% | expansion | Stock Titan | Myriad Genetics (NASDAQ: MYGN), Clairity and MagView launch AI breast risk platform - Stock Titan |
| 2026-01-15 | -3.3% | news | Seeking Alpha | Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2026-01-15 | -3.3% | news | Seeking Alpha | Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow |
| 2025-11-06 | -3.3% | news | Stock Titan | Myriad Genetics (NASDAQ: MYGN) to present 11 studies at NSGC on oncology and prenatal - Stock Titan |
| 2023-03-29 | -3.3% | news | Seeking Alpha | Myriad Genetics Stock: Do Not Expect Breakthroughs - Seeking Alpha |
| 2024-12-10 | -2.9% | legal | SEC EDGAR | MYGN 8-K: 5.02 and (SEC Filing) |
| 2025-08-18 | -2.9% | executive | Seeking Alpha | Myriad Genetics announces CFO appointment |
| 2025-08-18 | -2.9% | legal | SEC EDGAR | MYGN 8-K: 5.02 and (SEC Filing) |
| 2024-08-06 | +2.8% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2026-02-04 | -2.8% | news | simplywall.st | Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet? - simplywall.st |
| 2022-05-05 | +2.5% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2025-10-31 | +2.4% | news | Stock Titan | Myriad Genetics (NASDAQ: MYGN): GeneSight yields 21% higher response over 24 weeks - Stock Titan |
| 2026-01-14 | -2.4% | news | Seeking Alpha | Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha |
| 2026-03-17 | +2.2% | legal | Stock Titan | FDA approves genetic test to match ovarian cancer patients to Zejula - Stock Titan |
| 2024-11-07 | -2.1% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2022-09-13 | -2.1% | analyst | TradingView | MYGN Forecast — Price Target — Prediction for 2027 - TradingView |
| 2025-08-04 | -2.0% | earnings | Seeking Alpha | Myriad Genetics Q2 2025 Earnings Preview |
| 2025-04-04 | +2.0% | news | Intellectia AI | MYGN Forecast — Price Prediction for 2026. Should I Buy MYGN? - Intellectia AI |
| 2025-12-09 | +1.7% | news | StockStory | Why Myriad Genetics (MYGN) Stock Is Up Today - StockStory |
| 2025-12-09 | +1.7% | news | TradingView | Why Myriad Genetics (MYGN) Stock Is Up Today - TradingView |
| 2024-01-16 | +1.7% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2025-12-30 | -1.7% | news | Yahoo Finance | Should Myriad Genetics Stock Stay in Your Portfolio Right Now? - Yahoo Finance |
| 2026-03-31 | +1.6% | news | Seeking Alpha | Myriad Genetics: SOTP Suggests The Company Is Undervalued |
| 2026-03-31 | +1.6% | news | Seeking Alpha | Myriad Genetics: SOTP Suggests The Company Is Undervalued - Seeking Alpha |
| 2022-04-01 | +1.6% | legal | SEC EDGAR | MYGN 8-K: 8.01 (SEC Filing) |
| 2025-11-02 | +1.6% | earnings | Seeking Alpha | Myriad Genetics Q3 2025 Earnings Preview |
| 2025-11-01 | +1.6% | earnings | TradingView | What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings - TradingView |
| 2026-04-21 | -1.5% | earnings | MarketBeat | Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat |
| 2025-07-31 | -1.4% | news | Seeking Alpha | Myriad genetics announces new $200 million credit facility |
| 2025-07-31 | -1.4% | legal | SEC EDGAR | MYGN 8-K: 1.01, 2.03, 8.01 (SEC Filing) |
| 2026-03-16 | +1.3% | executive | Stock Titan | Myriad Genetics (MYGN) Chief Commercial Officer granted 226,804 RSUs - Stock Titan |
| 2026-03-16 | +1.3% | news | Stock Titan | Myriad Genetics (MYGN) CSO gets 173,196 RSUs, withholds 37,799 shares - Stock Titan |
| 2025-11-05 | -1.3% | earnings | Seeking Alpha | Myriad Genetics: Downgrading To "Hold" Rating On Break-Even Q3 Earnings |
| 2025-11-05 | -1.3% | earnings | Seeking Alpha | Myriad Genetics: Downgrading To "Hold" Rating On Break-Even Q3 Earnings - Seeking Alpha |
| 2023-12-21 | -1.2% | legal | SEC EDGAR | MYGN 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-02 | +1.2% | news | StockStory | 3 Healthcare Stocks with Open Questions |
| 2022-06-02 | +1.0% | legal | SEC EDGAR | MYGN 8-K: 5.02, 5.07 (SEC Filing) |
| 2024-06-18 | -0.9% | earnings | MarketBeat | Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests - MarketBeat |
| 2022-02-09 | +0.9% | legal | SEC EDGAR | MYGN 8-K: 5.02 and (SEC Filing) |
| 2025-12-22 | -0.9% | news | Yahoo Finance | Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - Yahoo Finance |
| 2026-02-13 | -0.9% | earnings | simplywall.st | Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding - simplywall.st |
| 2026-02-13 | -0.9% | news | DirectorsTalk Interviews | Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating a 79% Potential Upside Amidst Challenging Metrics - DirectorsTalk Interviews |
| 2026-04-15 | +0.8% | earnings | MarketBeat | Myriad Genetics, Inc. (NASDAQ:MYGN) Sees Significant Decline in Short Interest - MarketBeat |
| 2026-04-15 | +0.8% | earnings | MarketBeat | Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by TD Cowen - MarketBeat |
| 2026-04-15 | +0.8% | executive | Stock Titan | Myriad Genetics (NASDAQ: MYGN) COO has 1,069 shares withheld for RSU taxes - Stock Titan |
| 2026-04-15 | +0.8% | news | Stock Titan | Tax withholding trims Myriad Genetics (MYGN) CSO stake by 946 shares - Stock Titan |
| 2022-06-30 | +0.8% | legal | SEC EDGAR | MYGN 8-K: 5.02 (SEC Filing) |
| 2026-04-06 | -0.7% | news | Simply Wall St. | Myriad Genetics And 2 Other Penny Stocks To Watch Closely |
| 2026-04-06 | -0.7% | earnings | StockStory | Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks |
| 2026-04-06 | -0.7% | news | simplywall.st | Myriad Genetics And 2 Other Penny Stocks To Watch Closely - simplywall.st |
| 2026-04-06 | -0.7% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | Can Myriad Genetics (MYGN) Stock Beat Estimates | Price at $4.76, Up 0.21% - Late Breakout - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-06 | -0.7% | earnings | Xã Châu Thành | Can Myriad Genetics (MYGN) Stock Beat Estimates | Price at $4.76, Up 0.21% - Trending Volume Leaders - Xã Châu Thành |
| 2026-01-04 | -0.7% | news | AD HOC NEWS | The Truth About Myriad Genetics Inc: Is This DNA Stock a Sleeper Goldmine or Just Overhyped? - AD HOC NEWS |
| 2026-03-19 | +0.7% | news | Yahoo Finance | Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term - Yahoo Finance |
| 2025-11-11 | +0.6% | news | Stock Titan | Myriad (NASDAQ: MYGN) to join Wolfe, Piper Sandler conferences; live webcasts - Stock Titan |
| 2025-11-11 | +0.6% | news | TradingView | Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know - TradingView |
| 2023-05-03 | +0.6% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2026-04-07 | -0.5% | news | Stock Titan | BlackRock (NYSE: MYGN) holds 7.98M shares, 8.5% stake reported - Stock Titan |
| 2023-11-01 | -0.4% | legal | SEC EDGAR | MYGN 8-K: 5.02 and (SEC Filing) |
| 2022-01-11 | +0.4% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2023-11-13 | +0.3% | legal | SEC EDGAR | MYGN 8-K: 1.01 and (SEC Filing) |
| 2026-02-20 | +0.3% | earnings | Seeking Alpha | Myriad Genetics Q4 2025 Earnings Preview |
| 2021-11-09 | -0.3% | news | Nanalyze | Myriad Genetics Stock vs. Invitae Stock - Nanalyze |
| 2025-11-15 | +0.2% | news | Trefis | Can Myriad Genetics Stock Recover If Markets Fall? - Trefis |
| 2026-02-16 | +0.1% | earnings | Quiver Quantitative | Myriad Genetics to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 23, 2026 - Quiver Quantitative |
| 2026-03-23 | -0.1% | news | Stock Titan | Myriad Genetics (MYGN) CSO has shares withheld to cover RSU taxes - Stock Titan |
| 2026-03-23 | -0.1% | executive | Stock Titan | Myriad Genetics (MYGN) COO has 2,055 shares withheld to cover taxes - Stock Titan |
| 2026-03-23 | -0.1% | executive | Stock Titan | Myriad Genetics (MYGN) CFO uses 549 shares for RSU tax withholding - Stock Titan |
| 2022-02-24 | -0.0% | legal | SEC EDGAR | MYGN 8-K: 2.02 and (SEC Filing) |
| 2026-04-26 | — | news | MSN | MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain? - MSN |
| 2026-04-25 | — | news | StockStory | 3 Small-Cap Stocks We Think Twice About |